Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Endocrinology
•
Bone and Calcium Disorders
What can cause a vertebra to be hyperdense on bone density testing and thus excluded other than vertebral fracture or degenerative change?
Related Questions
Would you favor oral bisphosphonates over intravenous formulations for patients with hormone sensitive prostate cancer and androgen deprivation therapy (ADT) related osteopenia?
Is the 6-month post-operative calcium level a good indicator of patients' risk of recurrence of primary hyperparathyroidism?
Should we aim to reduce or stop thiazides in patients with thiazide-induced hypercalcemia given its similar risk profile to untreated primary hyperparathyroidism?
What is your experience with using anabolic therapy for treatment of osteoporosis in patients with EtOH cirrhosis and is one agent preferred over another (PTH analogue vs Evenity)?
Is there a role for cinacalcet in the management of PTHrP-mediated hypercalcemia?
Would you offer bisphosphonate therapy for infants with osteogenesis imperfecta type 11?
How long should a patient be treated with a bisphosphonate after a course of an anabolic medication has been completed?
Are there certain patients with primary hyperparathyroidism for whom you would consider percutaneous ablation of a parathyroid adenoma over surgical parathyroidectomy?
What treatment options are there for Fanconi syndrome-induced osteoporosis in young female patients outside of electrolyte and mineral replacement?
How do you counsel patients on the risks and benefits of strontium supplements for osteoporosis management?
